Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies

  • Cancers (Basel). 2024 Sep 6;16(17):3098. doi: 10.3390/cancers16173098.
Jingsong Zhang  1 ,  Juskaran S Chadha  1
Affiliations
  • 1. Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Abstract

There is an unmet need to develop new treatments for Metastatic Prostate Cancer. With the development of targeted radioligand therapies, bispecific T cell engagers, antibody-drug conjugates and chimeric antigen receptor T cell (CAR T) therapies, tumor-associated cell surface Antigens have emerged as new therapeutic targets in Metastatic Prostate Cancer. Ongoing and completed clinical trials targeting prostate-specific membrane antigen (PSMA), six transmembrane epithelial Antigens of the prostate 1 (STEAP1), kallikrein-related peptidase 2 (KLK2), prostate stem cell antigen (PSCA), and delta-like protein 3 (DLL3) in Metastatic Prostate Cancer were reviewed. Strategies for sequential or combinational therapy were discussed.

Keywords
CAR T; DLL3; KLK2; PSCA; PSMA; STEAP1; antibody–drug conjugate; bispecific T cell engagers; immunotherapy; prostate cancer.
Products